Chlamydia pneumoniae and atherosclerosis: The end?

Canadian Journal of Infectious Diseases and Medical Microbiology

Volumn 16, Issue 5, 2005, Pages 267-268

  Nicolle, L E ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MACROLIDE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ATHEROSCLEROSIS; CHLAMYDOPHILA PNEUMONIAE; CORONARY ARTERY DISEASE; EDITORIAL; HEART INFARCTION; HUMAN;

EID: 28344454334     PISSN: 17129532     EISSN: None     Source Type: Journal    
DOI: 10.1155/2005/617308     Document Type: Editorial

References (4)

1. Liu C, Waters DD. Chlamydia pneumoniae and atherosclerosis: From Koch postulates to clinical trials. Prog Cardiovasc Dis 2005;47:230-9.
2. Ngeh J, Anand V, Gupta S. Chlamydia pneumoniae and atherosclerosis - what we know and what we don't. Clin Microbiol Infect 2002;8:2-13.
3. Higgins JP. Chlamydia pneumoniae and coronary artery disease: The antibiotic trials. Mayo Clin Proc 2003;78:321-32.
4. Andraws R, Berger JS, Brown DL. Effects of antibiotic therapy on outcomes of patients with coronary artery disease: A meta-analysis of randomized controlled trials. JAMA 2005;293:2641-7.